Abstract
IL-24, previously known as melanoma differentiation antigen 7 (mda-7), is a member of the IL-10 family of cytokines and is mainly produced by Th2 cells and activated monocytes. Binding of IL-24 to either of its two heterodimeric receptors IL-20R1/IL-20R2 and IL-22R/IL-20R2 triggers phosphorylation and consequently activation of STAT3 and/or STAT1 in target tissues such as lung, testis, ovary, keratinocytes and skin. There is accumulating evidence that skin represents a major target tissue for IL-24 and related cytokines such as IL-19, -20, and -22. To date, the physiological properties of IL-24 are incompletely understood but available data indicate that it affects epidermal functions by increasing proliferation of dermal cells, suggestive of a possible role in psoriasis. However, the initial interest in IL-24 did not arise from its physiological signaling properties through its cognate receptors but rather because this cytokine has been reported to efficiently kill cancer cells independent of receptor expression and Jak-STAT signaling. These potentially intriguing properties have led to the development of adenovirally expressed IL-24, which was reported to induce selective cancer cell death in many different malignancies by activation or deactivation of a continuously growing list of distinct signaling pathways without harming surrounding healthy cells. In the present review we critically revisit and discuss the potential of IL-24 to become a selective and cancer cell-specific oncolytic drug and put these tentative properties into context with recent data on the physiological properties of this cytokine.
Keywords: Adenovirus, cancer, cytokine, IL-24, inflammation, skin disease, Malignant Cells, IL-20R1/IL-20R2, IL-22R/IL-20R2, STAT, tumor, Adenoviral, Ad-IL-24, (ornithine transcarbamylase), adeno-associated virus, INGN-241, (CRCAs), GST-IL-24, MAPK, (GADD), E-cadherin, APC, GSK-3, PTEN, PERK, p38 MAPK Pathway, UPR pathway, B-CLL, inflammatory, Epidermis, hyperplasia, melanoma
Current Medicinal Chemistry
Title: IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Volume: 17 Issue: 29
Author(s): C. Margue and S. Kreis
Affiliation:
Keywords: Adenovirus, cancer, cytokine, IL-24, inflammation, skin disease, Malignant Cells, IL-20R1/IL-20R2, IL-22R/IL-20R2, STAT, tumor, Adenoviral, Ad-IL-24, (ornithine transcarbamylase), adeno-associated virus, INGN-241, (CRCAs), GST-IL-24, MAPK, (GADD), E-cadherin, APC, GSK-3, PTEN, PERK, p38 MAPK Pathway, UPR pathway, B-CLL, inflammatory, Epidermis, hyperplasia, melanoma
Abstract: IL-24, previously known as melanoma differentiation antigen 7 (mda-7), is a member of the IL-10 family of cytokines and is mainly produced by Th2 cells and activated monocytes. Binding of IL-24 to either of its two heterodimeric receptors IL-20R1/IL-20R2 and IL-22R/IL-20R2 triggers phosphorylation and consequently activation of STAT3 and/or STAT1 in target tissues such as lung, testis, ovary, keratinocytes and skin. There is accumulating evidence that skin represents a major target tissue for IL-24 and related cytokines such as IL-19, -20, and -22. To date, the physiological properties of IL-24 are incompletely understood but available data indicate that it affects epidermal functions by increasing proliferation of dermal cells, suggestive of a possible role in psoriasis. However, the initial interest in IL-24 did not arise from its physiological signaling properties through its cognate receptors but rather because this cytokine has been reported to efficiently kill cancer cells independent of receptor expression and Jak-STAT signaling. These potentially intriguing properties have led to the development of adenovirally expressed IL-24, which was reported to induce selective cancer cell death in many different malignancies by activation or deactivation of a continuously growing list of distinct signaling pathways without harming surrounding healthy cells. In the present review we critically revisit and discuss the potential of IL-24 to become a selective and cancer cell-specific oncolytic drug and put these tentative properties into context with recent data on the physiological properties of this cytokine.
Export Options
About this article
Cite this article as:
Margue C. and Kreis S., IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176311
DOI https://dx.doi.org/10.2174/092986710793176311 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Application of Solvent Influenced Fluorescence-quenching and Enhancement to Develop a Highly Sensitive HPLC Methodology for Analysis of Resveratrol-PEG Conjugates
Current Pharmaceutical Analysis Synthesis and Anticancer Evaluation of some Newer 2, 5-Disubstituted-1,3, 4-Oxadiazole Analogues
Letters in Drug Design & Discovery The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design Effects of Tobacco Nicotine-Derived Nitrosamine Ketone (NNK) Exposures on Brain Alcohol Metabolizing Enzyme Activities
Drug Metabolism Letters Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry Exosomal miR-1298 and lncRNA-RP11-583F2.2 Expression in Hepatocellular Carcinoma
Current Genomics CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry Novel Paramagnetic Contrast Agents for Molecular Imaging and Targeted Drug Delivery
Current Pharmaceutical Biotechnology Photoacoustic Detection and Imaging of Cancer Using Nanoparticles as Optical Contrast Agents
Recent Patents on Nanomedicine <i>In Vivo</i> Evaluation of Inorganic Nanoparticle Complexes against CCL<sub>4</sub> Induced Hepatotoxicity
Current Drug Delivery Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry